RT Journal Article
SR Electronic
T1 Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE
JF Lupus Science & Medicine
JO Lupus Sci Med
FD Lupus Foundation of America
SP e000332
DO 10.1136/lupus-2019-000332
VO 6
IS 1
A1 Monica M Purmalek
A1 Philip M Carlucci
A1 Amit K Dey
A1 Maureen Sampson
A1 Yenealem Temesgen-Oyelakin
A1 Simantini Sakhardande
A1 Joseph B Lerman
A1 Alice Fike
A1 Michael Davis
A1 Jonathan H Chung
A1 Taufiq Salahuddin
A1 Zerai Manna
A1 Sarthak Gupta
A1 Marcus Y Chen
A1 Sarfaraz Hasni
A1 Nehal N Mehta
A1 Alan Remaley
A1 Mariana J Kaplan
YR 2019
UL http://lupus.bmj.com/content/6/1/e000332.abstract
AB Objective Subjects with SLE display an enhanced risk of atherosclerotic cardiovascular disease (CVD) that is not explained by Framingham risk. This study sought to investigate the utility of nuclear MR (NMR) spectroscopy measurements of serum lipoprotein particle counts and size and glycoprotein acetylation (GlycA) burden to predict coronary atherosclerosis in SLE.Methods Coronary plaque burden was assessed in SLE subjects and healthy controls using coronary CT angiography. Lipoproteins and GlycA were quantified by NMR spectroscopy.Results SLE subjects displayed statistically significant decreases in high-density lipoprotein (HDL) particle counts and increased very low-density lipoprotein (VLDL) particle counts compared with controls. Non-calcified coronary plaque burden (NCB) negatively associated with HDL subsets whereas it positively associated with VLDL particle counts in multivariate adjusted models. GlycA was significantly increased in SLE sera compared with controls. In contrast to high-sensitivity C reactive protein, elevations in GlycA in SLE significantly associated with NCB and insulin resistance (IR), though the association with NCB was no longer significant after adjusting for prednisone use.Conclusions Patients with SLE display a proatherogenic lipoprotein profile that may significantly contribute to the development of premature CVD. The results demonstrate that NMR measures of GlycA and lipoprotein profiles, beyond what is captured in routine clinical labs, could be a useful tool in assessing CVD risk in patients with SLE.